Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

IEatBearsForBreakfast Apr. 8 at 8:04 AM

$CAPR Let’s see what today brings.

0 · Reply

NetworkProDesk Apr. 8 at 5:58 AM

$CAPR biotech company Capricor Therapeutics.

0 · Reply

DragonAlgo Apr. 8 at 2:53 AM

🐉 $CAPR CALL — DragonAlgo® Signal Contract: CAPR CALL Expiry: 2026-09-18 | Strike: $35.00 | Type: CALL Option Plan (premium): Entry: $10.80 Stop: $7.78 TP1: $14.04 TP2: $18.36 TP3: $25.92 🔗 https://dragonalgo.com

0 · Reply

Atmwireless Apr. 8 at 2:26 AM

$CAPR fda gloating about moving at lightning speed for approvals…. But sure are dragging their feet when it comes to kicking vinay out. He should be escorted out of the building like Nicole was. On a brighter subject… tomorrow is the 45th day. FDA says their average approval time now is 45 days!

0 · Reply

Elon_Trumpet Apr. 8 at 2:11 AM

$CAPR feel like we might hit 40 pre approval if my namesake keeps his mouth shut

1 · Reply

Atmwireless Apr. 8 at 12:45 AM

$CAPR

0 · Reply

bond1971 Apr. 8 at 12:23 AM

$CAPR GET READY BULLS FOR MORE GREEN TOMORROW $$$

0 · Reply

Martinsucks Apr. 8 at 12:01 AM

$CAPR tomorrow is going to be excellent! Unless something happens overnight...

0 · Reply

dnfrs Apr. 7 at 11:38 PM

$CAPR In May , 2014 Linda Marbán, Ph.D., Chief Executive Officer of Capricor Therapeutics, said, “Licensing the exosome portfolio from Cedars-Sinai Medical Center is especially exciting because it allows Capricor to expand its regenerative medicine pipeline with a cell-free product platform that may have opportunities across various indications where inflammation, scarring, and cell death are part of the disease process. The unique properties of CDC-derived exosomes may allow us to develop novel cell-free therapeutics and expand our product portfolio. Though it is early in the development cycle, we are excited about this new platform technology. Capricor plans to explore development of the exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non- cardiovascular areas.” And in the latest CC she promised a 2026 update on the planned 2027 filing of "several" StealthX exosome therapeutics . Can hardly wait to learn more!

1 · Reply

satrasal Apr. 7 at 11:33 PM

$CAPR We still have 5 mil shorts under 10, about 1.6 in the 21-25 range and about .6 mil in the 26-36. Anyone remember that large block after hours 1-2 weeks ago? Someone thought it was NS, raising cash to pay capr the 80 mil, but i see no filings. We should see short interest on Thursday.... very curious.

1 · Reply